|
2014 SPONSOR |
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world¡¯s most serious illnesses: cardiovascular, cancer, gastrointestinal, infection.
Booth No. E042
Exhibition Item
Brilinta(Main item), Crestor, Atacand, Onglyza |
|
Oral Antiplatelet Agents in ACS Management |
Organized by CVRF and Supported by Educational Grant from Astrazeneca Korea |
Wednesday, April 23
6:00 PM - 8:00 PM
Room 1-1, Level 1 |
Moderator(s): Myeong-Ki Hong | Panelist(s): Dimitrios Alexopoulos, Kiyuk Chang, Gim-Hooi Choo | |
6:00 PM |
Dinner
|
6:30 PM |
Opening Remarks & Introduction
Speaker : Myeong-Ki Hong
|
6:35 PM |
Case Presentation 1: OAP Use in STEMI PCI
Case Presenter : Kiyuk Chang
|
6:45 PM |
Case Presentation 2: OAP Use in Rescue PCI
Case Presenter : Gim-Hooi Choo
|
6:55 PM |
Use of Oral Antiplatelet: Guidelines Implementation in Clinical Practice
Lecturer : Dimitrios Alexopoulos
|
7:40 PM |
Panel Discussion with Q&A
|
|
|
|
Explore a Choice of Treatment in ACS Patient Journey: Statin and Anti-platelet |
Organized by CVRF and Supported by Educational Grant from Astrazeneca Korea |
Thursday, April 24
12:45 PM - 1:45 PM
Room 1-1, Level 1 |
Moderator(s): Yangsoo Jang, Dong Joo Oh | Panelist(s): Dimitrios Alexopoulos, Kyung Woo Park | |
12:45 PM |
Opening Remarks
|
12:50 PM |
Statin for Better Outcome in Patients with ACS
Lecturer : Kyung Woo Park
|
1:15 PM |
Ticagrelor Beyond Antiplatelet Effect & Benefit in ¡°Real-World¡± Practice
Lecturer : Dimitrios Alexopoulos
|
1:40 PM |
Q & A
|
|
|
|
|
|
|
|
|
|
CardioVascular Research Foundation(CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
Tel: 82-2-3010-7255/ Business registration number: 215-82-06387
Copyright ¨Ï 2002 CVRF, Seoul, Korea. All rights reserved. |
|
|
|